



Antimicrobial Resistance in Gram-negative Bacteria

Guest Editor:

Prof. Dr. Yuji Morita

Department of Infection Control
Science, Meiji Pharmaceutical
University, 2-522-1 Noshio,
Kiyose, Tokyo, Japan

Deadline for manuscript
submissions:

closed (31 August 2019)

Message from the Guest Editor

Dear Colleagues,

Gram-negative bacteria possess an intrinsic resistance to many antimicrobials because of the bacterium's outer-membrane barrier, the presence of multidrug efflux transporters, and endogenous antimicrobial inactivation etc. Moreover, Gram-negative bacteria readily acquire resistance to antimicrobial agents via chromosomal mutations and lateral gene transfers. In order to overcome this problem, it is necessary to tackle the development of antibacterial agents, drug resistance inhibitors, anti-pathogenic factors and vaccines. Thus, this Special Issue features interdisciplinary studies that build our understanding of the underlying antimicrobial resistance in Gram-negative bacteria. It also covers studies on development of antibacterial agents and adjuvant against antimicrobial resistant Gram-negative bacteria.

Prof. Yuji Morita
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)